Schulhoff & Co. Inc. Boosts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Schulhoff & Co. Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,600 shares of the company’s stock after purchasing an additional 270 shares during the quarter. Schulhoff & Co. Inc.’s holdings in Medpace were worth $868,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Ashton Thomas Securities LLC bought a new position in Medpace during the third quarter valued at approximately $37,000. J.Safra Asset Management Corp grew its holdings in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. DT Investment Partners LLC bought a new position in shares of Medpace during the 2nd quarter valued at $41,000. Capital Performance Advisors LLP purchased a new position in Medpace in the 3rd quarter worth $46,000. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Medpace in the second quarter worth $52,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MEDP. Guggenheim reduced their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Robert W. Baird lowered Medpace from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $380.00.

Medpace Trading Up 0.3 %

Shares of Medpace stock opened at $361.94 on Thursday. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77. The company has a market cap of $11.25 billion, a P/E ratio of 31.69, a PEG ratio of 2.00 and a beta of 1.37. The company’s fifty day simple moving average is $341.97 and its two-hundred day simple moving average is $376.72.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the previous year, the company earned $2.22 earnings per share. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. Analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.